145 related articles for article (PubMed ID: 37114510)
1. Identification and exploration of quinazoline-1,2,3-triazole inhibitors targeting EGFR in lung cancer.
Kumar S; Sengupta S; Ali I; Gupta MK; Lalhlenmawia H; Azizov S; Kumar D
J Biomol Struct Dyn; 2023; 41(21):11353-11372. PubMed ID: 37114510
[TBL] [Abstract][Full Text] [Related]
2. Molecular docking and dynamics studies of 4-anilino quinazolines for epidermal growth factor receptor tyrosine kinase to find potent inhibitor.
Muthuvel SK; Elumalai E; K G; K H
J Recept Signal Transduct Res; 2018; 38(5-6):475-483. PubMed ID: 31038021
[TBL] [Abstract][Full Text] [Related]
3. In silico target specific design of potential quinazoline-based anti-NSCLC agents.
Mohammadnejadi E; Razzaghi-Asl N
J Biomol Struct Dyn; 2023 Dec; 41(20):10725-10736. PubMed ID: 36826424
[TBL] [Abstract][Full Text] [Related]
4. In-silico identification of small molecule benzofuran-1,2,3-triazole hybrids as potential inhibitors targeting EGFR in lung cancer via ligand-based pharmacophore modeling and molecular docking studies.
Kumar S; Ali I; Abbas F; Khan N; Gupta MK; Garg M; Kumar S; Kumar D
In Silico Pharmacol; 2023; 11(1):20. PubMed ID: 37575679
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of anti-EGFR potential of quinazoline derivatives using molecular docking: An in silico approach.
Tanveer F; Anwar MF; Siraj B; Zarina S
Biotechnol Appl Biochem; 2022 Jun; 69(3):1226-1237. PubMed ID: 34028091
[TBL] [Abstract][Full Text] [Related]
6. Molecular Modeling, Docking, Dynamics and Simulation of Gefitinib and its Derivatives with EGFR in Non-small Cell Lung Cancer.
Reddy PS; Lokhande KB; Nagar S; Reddy VD; Murthy PS; Swamy KV
Curr Comput Aided Drug Des; 2018; 14(3):246-252. PubMed ID: 29493460
[TBL] [Abstract][Full Text] [Related]
7. Molecular Docking, Pharmacokinetic and Molecular Simulation Analysis of Novel Mono-Carbonyl Curcumin Analogs as L858R/T790M/C797S Mutant EGFR Inhibitors.
Bhandari SV; Kuthe PV; Patil SM; Nagras OG; Sarkate AP; Chaudhari SY; Surve SV
Chem Biodivers; 2023 Nov; 20(11):e202301081. PubMed ID: 37793119
[TBL] [Abstract][Full Text] [Related]
8. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
[TBL] [Abstract][Full Text] [Related]
9. Identification of EGFR inhibitors as potential agents for cancer therapy: pharmacophore-based modeling, molecular docking, and molecular dynamics investigations.
Ashiru MA; Ogunyemi SO; Temionu OR; Ajibare AC; Cicero-Mfon NC; Ihekuna OA; Jagun MO; Abdulmumin L; Adisa QK; Asibor YE; Okorie CJ; Lawal MO; Babalola MO; Abdulrasaq IT; Salau LB; Olatunji IO; Bankole MA; Daud AB; Adeyemi AO
J Mol Model; 2023 Apr; 29(5):128. PubMed ID: 37016200
[TBL] [Abstract][Full Text] [Related]
10. Molecular dynamics, MM/PBSA and in vitro validation of a novel quinazoline-based EGFR tyrosine kinase inhibitor identified using structure-based in silico screening.
Ornnork N; Kiriwan D; Lirdprapamongkol K; Choowongkomon K; Svasti J; Eurtivong C
J Mol Graph Model; 2020 Sep; 99():107639. PubMed ID: 32534372
[TBL] [Abstract][Full Text] [Related]
11.
Kumar S; Ali I; Abbas F; Rana A; Pandey S; Garg M; Kumar D
J Biomol Struct Dyn; 2023 Aug; ():1-23. PubMed ID: 37646177
[TBL] [Abstract][Full Text] [Related]
12.
Imana SN; Ningsih EG; Tambunan USF
Pak J Biol Sci; 2020 Mar; 23(4):567-574. PubMed ID: 32363843
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies.
Altamimi AS; El-Azab AS; Abdelhamid SG; Alamri MA; Bayoumi AH; Alqahtani SM; Alabbas AB; Altharawi AI; Alossaimi MA; Mohamed MA
Molecules; 2021 May; 26(10):. PubMed ID: 34069962
[TBL] [Abstract][Full Text] [Related]
14. Discovery of the allosteric inhibitor from actinomyces metabolites to target EGFR
Saini R; Kumari S; Bhatnagar A; Singh A; Mishra A
Sci Rep; 2023 Jun; 13(1):8885. PubMed ID: 37264083
[TBL] [Abstract][Full Text] [Related]
15. Natural alkaloids targeting EGFR in non-small cell lung cancer: Molecular docking and ADMET predictions.
Saini N; Grewal AS; Lather V; Gahlawat SK
Chem Biol Interact; 2022 May; 358():109901. PubMed ID: 35341731
[TBL] [Abstract][Full Text] [Related]
16. Identification of tripeptides against tyrosine kinase domain of EGFR for lung cancer cell inhibition by in silico and in vitro studies.
Kiriwan D; Seetaha S; Jiwacharoenchai N; Tabtimmai L; Sousa SF; Songtawee N; Choowongkomon K
Chem Biol Drug Des; 2022 Mar; 99(3):456-469. PubMed ID: 34923743
[TBL] [Abstract][Full Text] [Related]
17. Identification of luteolin -7-glucoside and epicatechin gallate from
Maiti P; Nand M; Joshi T; Ramakrishnan MA; Chandra S
J Biomol Struct Dyn; 2021 Sep; 39(14):5048-5057. PubMed ID: 32579072
[TBL] [Abstract][Full Text] [Related]
18. Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses.
Rezki N; Almehmadi MA; Ihmaid S; Shehata AM; Omar AM; Ahmed HEA; Aouad MR
Bioorg Chem; 2020 Oct; 103():104133. PubMed ID: 32745759
[TBL] [Abstract][Full Text] [Related]
19. In Silico and In Vitro Evaluations of Fluorophoric Thiazolo-[2,3-b]quinazolinones as Anti-cancer Agents Targeting EGFR-TKD.
Mir SA; Dash GC; Meher RK; Mohanta PP; Chopdar KS; Mohapatra PK; Baitharu I; Behera AK; Raval MK; Nayak B
Appl Biochem Biotechnol; 2022 Oct; 194(10):4292-4318. PubMed ID: 35366187
[TBL] [Abstract][Full Text] [Related]
20. Mushrooms are potential foods against cancer: identified by molecular docking and molecular dynamics simulation.
Debnath S; Sen D
Nat Prod Res; 2022 May; 36(10):2604-2609. PubMed ID: 33974466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
